116 related articles for article (PubMed ID: 15946492)
41. The matrix metalloproteinase system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2006 Dec; 44(6):482-6. PubMed ID: 16338034
[TBL] [Abstract][Full Text] [Related]
42. [Zymography--method for quantitation of activity on gelatinase A (pro-MMP-2, 72 kDa) and gelatinase B (pro-MMP-9, 92 kDa) in serum of patients with breast cancer].
Sliwowska I; Kopczyński Z
Wiad Lek; 2007; 60(5-6):241-7. PubMed ID: 17966888
[TBL] [Abstract][Full Text] [Related]
43. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
44. The relation between pure papillary and follicular variant in papillary thyroid carcinoma.
Yuksel O; Kurukahvecioglu O; Ege B; Ekinci O; Aydin A; Poyraz A; Tezel E; Taneri F
Endocr Regul; 2008 Mar; 42(1):29-33. PubMed ID: 18333702
[TBL] [Abstract][Full Text] [Related]
45. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
46. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
Steven K; Poulsen AL
J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113
[TBL] [Abstract][Full Text] [Related]
47. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer.
Lin SY; Wang YY; Sheu WH
Clin Endocrinol (Oxf); 2003 Apr; 58(4):513-8. PubMed ID: 12641636
[TBL] [Abstract][Full Text] [Related]
48. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
49. [Correlation of cervical lymphatic metastasis to prognosis of glottic carcinoma: a report of 333 cases].
Zhang Q; Lai FY; Guo ZM; Zeng ZY; Song M; Yu WB; Yang CS
Ai Zheng; 2007 Oct; 26(10):1138-42. PubMed ID: 17927888
[TBL] [Abstract][Full Text] [Related]
50. Follicular thyroid carcinoma in an iodine-replete endemic goiter region: a prospectively collected, retrospectively analyzed clinical trial.
Asari R; Koperek O; Scheuba C; Riss P; Kaserer K; Hoffmann M; Niederle B
Ann Surg; 2009 Jun; 249(6):1023-31. PubMed ID: 19474675
[TBL] [Abstract][Full Text] [Related]
51. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer.
Machens A; Hauptmann S; Dralle H
Surgery; 2009 Feb; 145(2):176-81. PubMed ID: 19167972
[TBL] [Abstract][Full Text] [Related]
52. Detection of circulating thyroid cancer cells in patients with thyroid microcarcinomas.
Novosel T; Ritter HE; Gupta M; Harvey A; Mitchell J; Berber E; Siperstein A; Milas M
Surgery; 2009 Dec; 146(6):1081-9. PubMed ID: 19958935
[TBL] [Abstract][Full Text] [Related]
53. [Thyroglobulin levels in needle lymph node cytology for the detection of papillary thyroid cancer recurrence].
Véliz J; Brantes S; Ramos C; Aguayo J; Cáceres E; Herrera M; Barber A; Barría M; Wohllk N
Rev Med Chil; 2008 Sep; 136(9):1107-12. PubMed ID: 19030653
[TBL] [Abstract][Full Text] [Related]
54. [Predictive factors for level VI lymph node metastasis in papillary thyroid microcarcinoma].
Wang Y; Ji QH; Huang CP; Zhu YX; Zhang L
Zhonghua Wai Ke Za Zhi; 2008 Dec; 46(24):1899-901. PubMed ID: 19134382
[TBL] [Abstract][Full Text] [Related]
55. Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma.
Ito Y; Yoshida H; Kakudo K; Nakamura Y; Kuma K; Miyauchi A
Pathology; 2006 Oct; 38(5):421-5. PubMed ID: 17008280
[TBL] [Abstract][Full Text] [Related]
56. Correlations between papillary thyroid cancer and peripheral blood levels of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2.
Zhou SF; Hu SY; Ma L; Miao L; Mao WZ
Chin Med J (Engl); 2013; 126(10):1925-9. PubMed ID: 23673111
[TBL] [Abstract][Full Text] [Related]
57. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
Wang T; Jiang CX; Li Y; Liu X
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
[TBL] [Abstract][Full Text] [Related]
58. MMP-9-1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression.
Roncevic J; Djoric I; Selemetjev S; Jankovic J; Dencic TI; Bozic V; Cvejic D
Pathology; 2019 Jan; 51(1):55-61. PubMed ID: 30497805
[TBL] [Abstract][Full Text] [Related]
59. Serum levels of matrix metalloproteinase-9 predict lymph node metastasis in breast cancer patients.
Heo DS; Choi H; Yeom MY; Song BJ; Oh SJ
Oncol Rep; 2014 Apr; 31(4):1567-72. PubMed ID: 24481627
[TBL] [Abstract][Full Text] [Related]
60. Non-tumor-associated psammoma bodies in the thyroid.
Hunt JL; Barnes EL
Am J Clin Pathol; 2003 Jan; 119(1):90-4. PubMed ID: 12520702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
